Back to News
Market Impact: 0.25
CAPR Investor Reminder: Capricor Therapeutics Securities Fraud Class Action after 64% Stock Drop is Pending – Investors Notified to Contact BFA Law before September 28 Deadline
Source: Business Wire
Legal & Litigation
Capricor Therapeutics faces a pending securities-fraud class action following a 64% stock-price decline. The notice urges investors to contact BFA Law before the September 28 deadline, highlighting elevated litigation and investor-risk concerns for Capricor.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly negative
Sentiment Score
-0.65
Ticker Sentiment
CAPR-0.95
More News
- California AG Says Paramount-WBD Merger Would Hurt the State
- Microsoft exec called AI scraping the “largest theft of labor in human history”
- EPA immediately sued over plans to repeal climate rules for power plants
- UN fact-finding mission says US committed possible war crimes in Iran
- Paramount is getting an assist from a key California pol as it defends its Warner merger against AG Rob Bonta
- Europe's EU Kids Act would ban social media access for children under 13
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Portfolio Monitoring: Build an Alert Policy Analysts Can Audit
- The Great Divergence: North American Banking at the Crossroads of Monetary Policy and Agentic AI (Q4 2025 Bank Earnings)